ADC drugs are popular, and the drug company has introduced a number of new products through acquisitions

[Pharmaceutical Network Enterprise News] Recently, Huadong Medicine announced that it has completed all the approvals or approvals required by the relevant departments of China and Germany for the equity investment plan of Heidelberg Pharm.
According to public information, Heidelberg Pharma (formerly WILEX AG) is a global biopharmaceutical company focusing on the research and development of oncology ADC drug.
.At present, it has independently developed using its proprietary technology platform, and has established a differentiated advanced R&D pipelin.
The main products under development are HDP-101, HDP-102, HDP-103 and HDP-104.At the same time, Heidelberg Pharma has also successfully carried out a number of external cooperation to promote the transformation of technological achievement.
Out of optimism about its R&D pipeline, on February 27, 2022, Huadong Medicine signed the Equity Investment Agreement and the Product Exclusive License Agreement with Heidelberg Pharm.
According to the content of the agreement, Huadong Medicine will acquire a total of 35% of Heidelberg Pharma for 105 million euros, and obtain the exclusive development and commercialization rights of Heidelberg Pharma's research products HDP-101 and HDP-103 in 20 Asian countries and regions , the exclusive right of option (Opt-in) for the HDP-102 and HDP-104 products under development, and the right of first negotiation (ROFN) for the other two follow-up products under developmen.
It is understood that HDP-101 is an ATAC drug targeting B cell maturation antigen (BCMA), HDP-102 is an ATAC drug targeting CD37, and HDP-103 is an ATAC drug targeting prostate specific membrane antigen ( PSMA) ATAC drug.
The industry expects that this acquisition will accelerate Huadong Medicine to build a differentiated ADC independent research and development platform, strengthen and optimize the tumor product innovation chain and the ADC field ecological chai.
In fact, in recent years, Huadong Medicine has been continuously increasing its differentiated and in-depth layout in the ADC fiel.
It has successively invested in the cooperation of antibody R&D and production company Quanxin Bio, ADC linker and coupling technology company Nuo Ling Bio and other companie.
From the current point of view, Huadong Medicine's R&D technology and clinical registration capabilities in the ADC field have been further improve.
It is worth mentioning that in the future, it also plans to develop no less than 10 ADC innovative products within three years and actively promote registered clinical researc.
It is worth noting that, from an overall point of view, both Biotech and Big Pharma in China are actively deploying the ADC marke.
According to incomplete statistics, there are more than 170 ADCs under research in China, of which nearly 60 have entered the clinical stag.
Under such circumstances, it is inevitable for pharmaceutical companies to face more intense competitio.
It is expected in the industry that in the future, in order to enhance competitiveness and accelerate product development and commercialization, it is expected that pharmaceutical companies will become the norm in the ADC field through acquisitions and cooperatio.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.